Maturitas, 12 (1990) 373
Elsevier Scientific Publishers Ireland Ltd.

Author Index Volume 12

Aedo, A.-R. 333

Benedek-Jaszmann, L.J. 37
Bosson, D. 137
Byrjalsen, I. 79

Cabranes, J.A. 105
Christiansen, C. 79, 99, 247, 321

Dequeker, J. 1
Diczfalusy, E. 333

Ekelund, P. 51, 113
Elliesen, J. 127
Eriksson, O. 113
Escudero, G. 105

Geusens, P. 1

Ham, H. 137
Hamburger, S. 315
Haylen, B.T. 61
Hernandez, E.R. 105
Higa, H. 43
Hirvonen, E. 127
Hunter, M.S. 299

Jensen, J. 99, 321

Kicovic, P.M. 37
Kloosterboer, H.J. 37
Kono, S. 43
Koster, A. 345
Kuhl, H. 171

Landgren, B.-M. 333
Lauritzen, C. 199
L'Hermite, M. 215

Mellstrom, D. 51, 113
Milsom, I. 51, 113
Molander, U. 51, 113

Nilas, L. 321

Parsons, K.F. 61
Parys, B.T. 61
Penttila, I. 89
Peretz, A. 137
Perez del Molino, J. 105

Rico, H. 105
Riis, B.J. 79, 99, 247
Rijpkema, A.H.M. 259
Robyn, C. 137
Rozenberg, S. 137
Ruijs, A.H.C. 259

Saarikoski, S. 89
Sarrel, P.M. 287
Schlemmer, A. 99
Schmidt-Gollwitzer, K. 127
Sunagawa, H. 43
Sunagawa, Y. 43

van der Sanden, A.A. 259
van Keep, P.A. 163
Vermeulen, A. 121

Yliskoski, M. 89

Maturitas, 12 (1990) 373
Elsevier Scientific Publishers Ireland Ltd.

Author Index Volume 12

Aedo, A.-R. 333

Benedek-Jaszmann, L.J. 37
Bosson, D. 137
Byrjalsen, I. 79

Cabranes, J.A. 105
Christiansen, C. 79, 99, 247, 321

Dequeker, J. 1
Diczfalusy, E. 333

Ekelund, P. 51, 113
Elliesen, J. 127
Eriksson, O. 113
Escudero, G. 105

Geusens, P. 1

Ham, H. 137
Hamburger, S. 315
Haylen, B.T. 61
Hernandez, E.R. 105
Higa, H. 43
Hirvonen, E. 127
Hunter, M.S. 299

Jensen, J. 99, 321

Kicovic, P.M. 37
Kloosterboer, H.J. 37
Kono, S. 43
Koster, A. 345
Kuhl, H. 171

Landgren, B.-M. 333
Lauritzen, C. 199
L'Hermite, M. 215

Mellstrom, D. 51, 113
Milsom, I. 51, 113
Molander, U. 51, 113

Nilas, L. 321

Parsons, K.F. 61
Parys, B.T. 61
Penttila, I. 89
Peretz, A. 137
Perez del Molino, J. 105

Rico, H. 105
Riis, B.J. 79, 99, 247
Rijpkema, A.H.M. 259
Robyn, C. 137
Rozenberg, S. 137
Ruijs, A.H.C. 259

Saarikoski, S. 89
Sarrel, P.M. 287
Schlemmer, A. 99
Schmidt-Gollwitzer, K. 127
Sunagawa, H. 43
Sunagawa, Y. 43

van der Sanden, A.A. 259
van Keep, P.A. 163
Vermeulen, A. 121

Yliskoski, M. 89

Maturitas, 12 (1990) 375—377
Elsevier Scientific Publishers Ireland Ltd.

Subject Index Volume 12

Age of menopause, mean age of menopause, secular trend, 43
Aging, osteoporosis, oestrogens, androgens, steroid hormones, bone parameters, 137
Androgens, osteoporosis, oestrogens, steroid hormones, bone parameters, aging, 137
Androstenedione, gonadotrophins, endogenous oestrogens, post-menopausal smokers, 99

Blood flow, estrogens, progestins, cardioprotection, 287
Bone mineral content, hormone replacement therapy, lipoproteins, oestradiol valerate, cyproterone acetate, norgestrel, 127
Bone parameters, osteoporosis, oestrogens, androgens, steroid hormones, aging, 137

Calcium pidolate, involutional oesteoporosis, parathyroid hormone, growth hormone, osteocalcin, 105
Cardioprotection, estrogens, progestins, blood flow, 287
Carry-over effect, progestogen treatment, norethisterone, progesterone, 89
Climacteric complaints, oestrogen-progestogen substitution, prevention of metabolic oestrogen deficiency diseases, side effects, modes of medication, 199
Climacteric symptoms, hormone replacement, prevalence, population study, reason for treatment, 345
Cyproterone acetate, hormone replacement therapy, lipoproteins, bone mineral content, oestradiol valerate, norgestrel, 127

Diet, obesity, plasma lipids, exercise, menopause, 121

Emotional aspects, menopause, hormone replacement therapy, psychological, sexuality, 299
Endogenous oestrogens, androstenedione, gonadotrophins, post-menopausal smokers, 99
Endometrial status, placental protein 14, oestrogen/progestogen status, 79
Epidemiology, urinary incontinence, prevalence, vaginal discharge, oestrogens, 51
Estrogens, progestins, blood flow, cardioprotection, 287
Estrogen replacement therapy, risk, 215
Exercise, obesity, plasma lipids, diet, menopause, 121

Future, hormone replacement therapy, history, rationale, 163

Gonadotrophins, androstenedione, endogenous oestrogens, post-menopausal smokers, 99
Growth hormone, involutional oesteoporosis, calcium pidolate, parathyroid hormone, osteocalcin, 105

High-density lipoprotein, long-term, lipids, menopause, Org OD 14, 37
History, hormone replacement therapy, rationale, future, 163
Hormone replacement, prevalence, climacteric symptoms, population study, reason for treatment, 345
Hormone replacement therapy, history, rationale, future, 163
Hormone replacement therapy, lipoproteins, bone mineral content, oestradiol valerate, cyproterone acetate, norgestrel, 127
Hormone replacement therapy, menopause, psychological, sexuality, emotional aspects, 299
Hormone replacement therapy, oestrogens, progestogens, post-menopause, lipoproteins, 259
Hormone replacement therapy, risk factors for osteoporosis, screening for risk of osteoporosis, 247

Involutional oesteoporosis, calcium pidolate, parathyroid hormone, growth hormone, osteocalcin, 105
Lipids, long-term, high-density lipoprotein, menopause, Org OD 14, 37
Lipids, menopause, lipoproteins, 321

Lipoproteins, hormone replacement therapy, bone mineral content, oestradiol valerate, cyproterone acetate, norgestrel, 127
Lipoproteins, menopause, lipids, 321
Lipoproteins, oestrogens, progestogens, post-menopause, hormone replacement therapy, 259
Liver metabolism, pharmacokinetics, oestrogens, progestogens, 171
Long-term, high-density lipoprotein, lipids, menopause, Org OD 14, 37

Mean age of menopause, age of menopause, secular trend, 43
Menopause, hormone replacement therapy, psychological, sexuality, emotional aspects, 299
Menopause, lipids, lipoproteins, 321
Menopause, long-term, high-density lipoprotein, lipids, Org OD 14, 37
Menopause, obesity, plasma lipids, diet, exercise, 121
Menopause, oestrogen therapy, pharmacokinetics, metabolism, 333
Metabolism, menopause, oestrogen therapy, pharmacokinetics, 333
Modes of medication, oestrogen-progestogen substitution, climacteric complaints, prevention of metabolic oestrogen deficiency diseases, side effects, 199

Norethisterone, progestogen treatment, progesterone, carry-over effect, 89
Norgestrel, hormone replacement therapy, lipoproteins, bone mineral content, oestradiol valerate, cyproterone acetate, 127

Obesity, plasma lipids, diet, exercise, menopause, 121
Oestradiol valerate, hormone replacement therapy, lipoproteins, bone mineral content, cyproterone acetate, norgestrel, 127
Oestriol, urogenital symptoms, Post-menopause, 113
Oestrogen-progestogen substitution, climacteric complaints, prevention of metabolic oestrogen deficiency diseases, side effects, modes of medication, 199
Oestrogen/progestogen status, placental protein 14, endometrial status, 79
Oestrogens, osteoporosis, androgens, steroid hormones, bone parameters, aging, 137
Oestrogens, pharmacokinetics, progestogens, liver metabolism, 171
Oestrogens, progestogens, post-menopause, lipoproteins, hormone replacement therapy, 259
Oestrogens, urinary incontinence, prevalence, epidemiology, vaginal discharge, 51
Oestrogen therapy, menopause, pharmacokinetics, metabolism, 333
Org OD 14, long-term, high-density lipoprotein, lipids, menopause, 37
Osteocalcin, involutional oesteoporosis, calcium pidolate, parathyroid hormone, growth hormone, 105
Osteoporosis, oestrogens, androgens, steroid hormones, bone parameters, aging, 137

Parathyroid hormone, involutional oesteoporosis, calcium pidolate, growth hormone, osteocalcin, 105
Pharmacokinetics, menopause, oestrogen therapy, metabolism, 333
Pharmacokinetics, oestrogens, progestogens, liver metabolism, 171
Placental protein 14, endometrial status, oestrogen/progestogen status, 79
Plasma lipids, obesity, diet, exercise, menopause, 121
Population study, hormone replacement, prevalence, climacteric symptoms, reason for treatment, 345
Post-menopausal smokers, androstenedione, gonadotrophins, endogenous oestrogens, 99
Post-menopause, oestriol, urogenital symptoms, 113
Post-menopause, oestrogens, progestogens, lipoproteins, hormone replacement therapy, 259
Prevalence, hormone replacement, climacteric symptoms, population study, reason for treatment, 345
Prevalence, urinary incontinence, epidemiology, vaginal discharge, oestrogens, 51
Prevention of metabolic oestrogen deficiency diseases, oestrogen-progestogen substitution, climacteric complaints, side effects, modes of medication, 199
Progesterone, progestogen treatment, norethisterone, carry-over effect, 89
Progestins, estrogens, blood flow, cardioprotection, 287
Progestogens, oestrogens, post-menopause, lipoproteins, hormone replacement therapy, 259
Progestogens, pharmacokinetics, Oestrogens, liver metabolism, 171

Progestogen treatment, norethisterone, progesterone, carry-over effect, 89
Psychological, menopause, hormone replacement therapy, sexuality, emotional aspects, 299

Rationale, hormone replacement therapy, history, future, 163
Reason for treatment. hormone replacement, prevalence, climacteric symptoms, population study, 345
Risk, estrogen replacement therapy, 215
Risk factors for osteoporosis, screening for risk of osteoporosis, hormone replacement therapy, 247

Screening for risk of osteoporosis, risk factors for osteoporosis, hormone replacement therapy, 247
Secular trend, age of menopause, mean age of menopause, 43
Sexuality, menopause, hormone replacement therapy, psychological, emotional aspects, 299
Side effects, oestrogen-progestogen substitution, climacteric complaints, prevention of metabolic oestrogen deficiency diseases, modes of medication, 199
Steroid hormones, osteoporosis, oestrogens, androgens, bone parameters, aging, 137

Total hysterectomy, urodynamics, 61

Urinary incontinence, prevalence, epidemiology, vaginal discharge, oestrogens, 51
Urodynamics, total hysterectomy, 61
Urogenital symptoms, oestriol, post-menopause, 113

Vaginal discharge, urinary incontinence, prevalence, epidemiology, oestrogens, 51